August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
25 citations
,
April 2019 in “Journal of The American Academy of Dermatology” Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
Onabotulinum toxin A may help treat trichotillomania and promote hair growth.
22 citations
,
April 2013 in “Dermatologic surgery” Bimatoprost effectively and safely improves eyebrow appearance.
1 citations
,
June 2022 in “JAMA” Baricitinib, a medication taken by mouth, was effective in regrowing hair for people with severe hair loss.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology” March 2019 in “Reactions Weekly”
4 citations
,
September 2017 in “Dermatologic surgery” The combination therapy improved skin pigmentation.
July 2025 in “Pakistan Journal of Intensive Care Medicine” Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
146 citations
,
July 2003 in “Journal of the American Academy of Dermatology” Clobetasol propionate ointment can help some people with total hair loss regrow hair.
22 citations
,
June 1991 in “Clinical Therapeutics” Oxiconazole nitrate cream is effective and safe for treating various fungal skin infections.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
6 citations
,
May 2024 in “JAAD Case Reports” Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is the most effective treatment for alopecia areata.
2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
7 citations
,
May 2018 in “Curēus” Bimatoprost 0.03% solution effectively promotes eyebrow growth.
3 citations
,
April 2025 in “American Journal of Clinical Dermatology” Baricitinib is generally safe for long-term use in treating severe alopecia areata.
December 2025 in “Frontiers in Medicine” Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
2 citations
,
February 2016 in “British Journal of Dermatology” Bimatoprost solution 0.03% is effective for treating sparse eyelashes.
1 citations
,
April 2016 in “Journal of the American Academy of Dermatology”
January 2025 in “Journal of Cutaneous Immunology and Allergy” Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
Baricitinib may effectively treat oral lichen planus.
September 2010 in “Reactions weekly” The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.
3 citations
,
September 2022 in “Journal of the American Academy of Dermatology” Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
3 citations
,
January 2025 in “International Journal of Biological Macromolecules” A new microneedle patch effectively promotes hair regrowth with less frequent dosing.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.